Bryan F. Cox sold $1,299 of TLSI
Chief of Research at TriSalus Life Sciences, Inc.. 296 shares at an average of $4.39, traded Oct 5, 2026, filed Oct 7, 2026.
Score components
- +15RoleOfficer
- 0Trade size$1k at market
- 0Share of holdings soldSold 0.2% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-065326, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 5, 2026 | SOpen-market sale Common Stock | -296 | $4.39 | $1,299 | 162,805 | 5 d ago |
Related signals
Other insiders at TriSalus Life Sciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | TriSalus Life Sciences, Inc. | Richard Marshak Chief Commercial Officer | $1,427 325 shares | -0% | |
| 30Weak | TriSalus Life Sciences, Inc. | Jennifer Stevens Chief Regulatory Officer | $1,387 316 shares | -0% | |
| 30Weak | TriSalus Life Sciences, Inc. | Bryan F. Cox Chief of Research | $25k 4,764 shares | -4% | |
| 30Weak | TriSalus Life Sciences, Inc. | Jodi Devlin Chief of Clinical Operations | $25k 4,764 shares | -8% | |
| 36Weak | TriSalus Life Sciences, Inc. | Richard Marshak Chief Commercial Officer | $34k 6,597 shares | -9% | |
| 41Moderate | TriSalus Life Sciences, Inc. | Jennifer Stevens Chief Regulatory Officer | $45k 8,704 shares | -10% | |
| 15Weak | TLSIsell TriSalus Life Sciences, Inc. | Bryan F. Cox CHIEF SCIENTIFIC & MANUFACT. | $1,394 314 shares | -0% | |
| 20Weak | TLSIbuy TriSalus Life Sciences, Inc. | Frankenius Equity AB owner | $250k 62,972 shares | +1% | |
| 30Weak | TLSIsell TriSalus Life Sciences, Inc. | Arjun JJ Desai director | $111k 30,000 shares | -11% | |
| 26Weak | TLSIbuy TriSalus Life Sciences, Inc. | Mats Wahlstrom director, owner | $23k 5,000 shares | +47% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.